Thermo Fisher Acquires Clario for $10 Billion
“`html
Thermo Fisher to Acquire Clario in Multi-Billion Dollar Deal
Table of Contents
Thermo Fisher Scientific is set to acquire Clario, a healthcare technology company, in a deal that could be one of the largest private equity exits of the year.
Deal Details and Company Background
Clario, founded in 2021 through the merger of health tech groups ERT and Bioclinica, specializes in providing technology solutions for clinical trials. The company is majority-owned by Nordic Capital, a Stockholm-based private equity firm. Minority investors include Astorg Partners,Novo Holdings,and Cinven.
Prior to the acquisition announcement,Clario’s private equity backers had reportedly been considering an initial public offering (IPO) for the group. The financial terms of the deal were not instantly disclosed, but analysts anticipate a valuation exceeding several billion dollars.
Thermo Fisher’s Acquisition Strategy
This deal would represent Thermo Fisher’s largest acquisition sence 2021,when it purchased contract research institution PPD for $17.4 billion according to Thermo Fisher’s official press release. Earlier in 2024, the company acquired Solventum’s filtration unit for $4.1 billion. These acquisitions demonstrate Thermo Fisher’s aggressive strategy to expand its presence in the life sciences and healthcare sectors.
Thermo Fisher, Clario, Nordic Capital, Astorg Partners, Novo Holdings, and Cinven did not immediatly respond to requests for comment.
Market Context and Thermo Fisher’s Performance
The acquisition occurs during a period of volatility for Thermo Fisher and the broader healthcare industry. Earlier in 2024, the company’s shares experienced a decline due to investor concerns regarding potential cuts to the National Institutes of Health (NIH) funding under the trump governance. However, the stock has since recovered.
As of October 29, 2024, Thermo Fisher shares are up 6% year-to-date, with a market capitalization of $210 billion. this positive performance reflects investor confidence in the company’s long-term growth prospects.
| Metric | Value (October 29, 2024) |
|---|---|
| Year-to-Date Share Increase | 6% |
| Market Capitalization | $210 Billion |
| Largest acquisition (Prior to Clario) | $17.4 Billion (PPD, 2021) |
Implications for the Clinical Trial Technology Market
The acquisition of Clario is expected to have significant implications for the clinical trial technology market.